tirzepatide breastfeeding safety GLP-1s While Breastfeeding: Safety, Evidence & Medical Guidance – PlexusDx Mounjaro and Breastfeeding: Safety Guidance

Tirzepatide has a similar side effect profile as GLP-1 medications, and research has shown that diarrhea typically lasts for about three days in people who take GLP-1s for obesity

But this table gives a useful framework for people considering switching from semaglutide to tirzepatide or trying to understand how the semaglutide to tirzepatide conversion chart works in practice

Month 6 (12.5 mg): ~22 lb

Cystatin C was determined using a turbidimetric assay (Roche Cobas Chemistry Analyzer)

However, Mounjaro is only FDA-approved for the treatment of type 2 diabetes - not weight loss

Clinical studies show modest weight loss of 2-5 pounds over 12 weeks, with more significant improvements in metabolic markers like fasting glucose and HbA1c